About InVivoMAb anti-mouse IL-25 The 2C3 monoclonal antibody reacts with mouse IL-25, also known as IL-17E and is a member of the IL-17 family of cytokines. IL-25 is a potent activator of type-2 immune responses and induces the expression of IL-4, IL-5, and IL-13. IL-25 is expressed in several tissues, including lung, stomach, small intestine, and colon and in cell types such as macrophages and epithelial cells in the gut, Th2 cells, mast cells, and NKT cells. IL-25 mediates its biological effects through the receptor IL-17BR, which forms a receptor complex with IL-17RA, both being essential for IL-25 effector functions. IL-25-induced inflammation is typically characterized by elevated levels of type-2 cytokines and serum IgE and IgG1. IL-25 plays a role in Th2 type inflammatory diseases, such as asthma, ulcerative colitis, and atopic dermatitis. The 2C3 antibody has been shown to neutralize IL-25 in vivo and improve pathology in mouse models of colitis and asthma. InVivoMAb anti-mouse IL-25 Specifications IsotypeMouse IgG1, κ Recommended Isotype Control(s)InVivoMAb mouse IgG1 isotype control, unknown specificity Recommended Dilution BufferInVivoPure pH 7.0 Dilution Buffer ImmunogenRecombinant mouse IL-25 Reported Applicationsin vivo IL-25 neutralization FormulationPBS, pH 7.0 Contains no stabilizers or preservatives Endotoxin<2EU/mg (<0.002EU/μg) Determined by LAL gel clotting assay Aggregation<5% Determined by SEC Purity>95% Determined by SDS-PAGE Sterility0.2 μm filtration ProductionPurified from cell culture supernatant in an animal-free facility PurificationProtein G Molecular Weight150 kDa StorageThe antibody solution should be stored at the stock concentration at 4°C. Do not freeze. Application ReferencesInVivoMAb anti-mouse IL-25 (CLONE: 2C3)Khodoun MV, Tomar S, Tocker JE, Wang YH, Finkelman FD (2018). "Prevention of food allergy development and suppression of established food allergy by neutralization of thymic stromal lymphopoietin, IL-25, and IL-33" J Allergy Clin Immunol 141(1):171-179.e1. PubMedFood allergy (FA) is an increasing problem that has no approved treatment. The pro-TH2 cytokines IL-25, IL-33, and thymic stromal lymphopoietin (TSLP) are associated with FA, and mAbs to these cytokines are reported to suppress murine FA development.Camelo A, Barlow JL, Drynan LF, Neill DR, Ballantyne SJ, Wong SH, Pannell R, Gao W, Wrigley K, Sprenkle J, McKenzie AN (2012). "Blocking IL-25 signalling protects against gut inflammation in a type-2 model of colitis by suppressing nuocyte and NKT derived IL-13" J Gastroenterol 47(11):1198-211. PubMedInterleukin-25 (IL-25) is a potent activator of type-2 immune responses. Mucosal inflammation in ulcerative colitis is driven by type-2 cytokines. We have previously shown that a neutralizing anti-IL-25 antibody abrogated airways hyperreactivity in an experimental model of lung allergy. Therefore, we asked whether blocking IL-25 via neutralizing antibodies against the ligand or its receptor IL-17BR could protect against inflammation in an oxazolone-induced mouse model of colitis.Ballantyne SJ, Barlow JL, Jolin HE, Nath P, Williams AS, Chung KF, Sturton G, Wong SH, McKenzie AN (2007). "Blocking IL-25 prevents airway hyperresponsiveness in allergic asthma" J Allergy Clin Immunol 120(6):1324-31. PubMedIL-25 (IL-17E), a member of the IL-17 family of immunoregulatory cytokines, has been implicated in the regulation of type 2 immunity. Its roles in antigen-driven airway inflammation and airway hyperresponsiveness (AHR) remain to be fully established.
